Conference Reports for NATAP

Back

12th Conference on Retroviruses and Opportunistic Infections (CROI) Feb 22-25, 2005 Boston, MA     Tenofovir and Kidney Toxicity: What do the studies show? - Written for NATAP Judith Aberg, MD, Bellevue Hospital, New York University Medical Center (04/14/04)   Enfuvirtide (ENF, T-20) Resistance, fast and pretty complete, studies from 12th CROI - Written for NATAP by Nancy Shulman, MD, Stanford University (04/06/04)   Body Shape Changes in HIV-Infected Persons - (04/06/04)   Key clinical studies in initial and switch therapy - Dr Graeme Moyle MD, MBBS (03/17/04)   Resistance part II (ddI and tipranavir resistance news) - Report Written by Nancy Shulman (03/17/04)   Nevirapine MTCT--Drug resistance at the 12th CROI - Report Written by Nancy Shulman (03/17/04)   Switch to Tenofovir Improved Lipids, Fat Loss - (03/15/04)   FDA Reports Higher Abacavir Hypersensitivity, 8% vs 5% - (03/15/04)   New Antiretrovirals at 12th CROI - Reported for NATAP by Mike Youle, MD - (03/10/04)   Prevention of mother-to-child transmission and nevirapine resistance - Reported for NATAP by David Margolis, MD - (03/09/04)   Innate Immunity: natural cellular mechanisms that battle HIV - Reported for NATAP by David Margolis, MD - (03/09/04)   Predicting Response to DDI - Reported for NATAP by David Margolis, MD - (03/09/04)   Choosing When to Use Tipranavir - Reported for NATAP by David Margolis, MD - (03/09/04)   HIV latency and persistent, low-level viremia - Reported for NATAP by David Margolis, MD - (03/09/04)   Leading Causes of Death in HIV....liver disease, AIDS, heart disease, malignancies - Reported for NATAP by David Margolis, MD - (03/09/04)   12th CROI HCV Report - (03/08/04)   CLINICAL PHARMACOLOGY AT THE 12th CROI- John G. Gerber, M.D. (03/08/04)   "Entecavir in HIV/HBV Co-Infected Patients: Safety and Efficacy in a Phase II Study (ETV-038)" - (03/08/04)   Liver Transplants in Hepatitis/HIV Coinfection at 12th CROI - (03/08/04)   Accelerated Liver Disease Progression in HCV/HIV Coinfection - (03/07/04)   Effect of Aging on Epidemiologic and Clinical Features in HIV-infected Individuals with Neurological Disorders - (03/07/04)   Impact of HAART on NeuroAIDS - (03/07/04)   Kaletra Independently Reduces HIV Replication in Cerebrospinal Fluid - (03/07/04)   DAPD + Fuzeon Pilot Study: ACTG 5118 - (03/07/04)   Advancing towards the therapeutic use of chemokine receptor blockade (CCR5-Entry Inhibitors) - Reported for NATAP by David Margolis, MD - (03/07/04)   Improved Lipids After Switch to Reyataz - (03/04/04)   Switch to ATV/r Improves Lipids - (03/04/04)   Tenofovir for HBV/HIV Coinfection - (03/03/04)   "Beyond Serum Creatinine: Identification of Renal Insufficiency Using GFR: Implications for Clinical Research and Care" - (03/03/04)   Reyataz/r: 96 week Study 045 results - (03/03/04)   Improving the Clinical Assessment of Renal Function in HIV - (03/02/04)   Decline in Renal Function Associated with Tenofovir DF (TDF) Compared to Nucleoside Reverse Transcriptase Inhibitor (NRTI) Treatment - (03/02/04)   Switch for Lipoatrophy to Abacavir or LPV/r+NVP - (03/02/04)   Switching to Tenofovir or Lower d4T Dose Improves Lipids/Limb & Total Fat - (03/02/04)   Triple NRTI Regimen: Combivir+Tenofovir - (03/02/04)   Sexual HCV Transmission Reported Among MSM - (03/02/04)   AZT Causes Anemia During Ribavirin/Interferon Therapy; EPO Improves Anemia - (03/01/04)   HIV Prevalence Among Blacks Increases in Federal Govt Survey - (03/01/04)   Two New Viruses Reported Belonging to AIDS Family - (03/01/04)   TMC278, new NNRTI, 7-day study results - (03/01/04)   PA-457, new HIV drug, maturation inhibitor - (03/01/04)   RAVE Study: switch to tenofovir or abacavir from AZT or d4T - (03/01/04)   Merck Integrase Inhibitor: -1.8 log reduction in 10-day study - (03/01/04)   TMC114/r in 3-Class Experienced Patients: 24-week interim analysis - (03/01/04)   24 Week RESIST Study Analysis: the efficacy of tipranavir/ritonavir is superior to lopinavir/r, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen (OBR) - (03/01/04)   Switching to Thymidine Analogue Sparing or Nuke Sparing Regimen improves Lipoatrophy: 24 week results of a prospective randomized clinical trial, AACTG 5110 - (02/25/04)   Switching off AZT or d4T to Tenofovir or Abacavir Improves Limb Fat After 48 weeks - (02/25/04)   IMPACT OF BASELINE GENOTYPIC RESISTANCE ON RESPONSE TO TIPRANAVIR/r in RESIST STUDIES - (02/25/04)   24 Week RESIST Study Analysis: the efficacy of tipranavir/ritonavir - (02/25/04)